Arno Therapeutics Announces Poster Presentation At ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity Of AR-42
Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on oncology therapeutics, today announced the presentation of a poster at the annual American Society of Hematology (ASH) meeting that describes the preclinical activity of Arno’s drug candidate AR-42 against leukemia stem cells (LSCs). AR-42 is a broad spectrum inhibitor of both histone and non-histone deacetylation proteins that demonstrated potent activity against Acute Myeloid Leukemia (AML) stem cells…
Related News:
Stem Cell Therapeutics Corp. Announces Presentation at 2nd Annual HOPE Conference for Parkinson's
Osiris Therapeutics Announces Cardiac Stem Cell Therapy Presentation At BMT Tandem Meeting
Stem Cell Therapeutics Corp. Announces Presentation at EDC's 8th Annual Life Science Conference, BioTech 2009